Metrics Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece
Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece
Pageviews and PDF downloads
Top Countries | |
---|---|
19 | |
16 | |
8 | |
8 | |
4 | |
4 | |
3 | |
2 | |
2 | |
2 |